ITMCTR2000003169
Not yet recruiting
Phase 1
A clinical study evaluating the safety and tolerability of microRNA2911 plasmids in healthy adults
anjing University0 sitesTBD
Conditionsovel Coronavirus Pneumonia (COVID-19)
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- ovel Coronavirus Pneumonia (COVID-19)
- Sponsor
- anjing University
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Healthy male or female subjects \>\=18 years old at the date of signing the informed consent;
- •2\. Male body weight 50kg, female body weight \>\=45kg, body mass index (BMI) in the range of 19\-28kg / m2 (including 19 and 28\) (BMI \= weight (kg) / height 2 (M2\));
- •3\. The results of physical examination, vital signs, blood routine, urine routine, blood biochemistry, blood coagulation, abdominal B\-ultrasound, chest X\-ray and other examinations in the screening period must be within the normal range consistent with age and gender, or meet the requirements of the program, or be judged as NCS if they are beyond the normal range;
- •4\. 12 lead ECG was normal, QTCF was less than 430ms in men and 450 ms in women; QTc interval was corrected by friderica formula (QTCF \= QT / (RR ^ 0\.33\), RR was the standardized heart rate value, which was obtained by dividing 60 by heart rate);
- •5\. Pregnancy test is negative in women of childbearing age;
- •6\. Agree to abstain or take effective non drug contraceptive measures within at least 3 months from screening to the last study drug administration (female subjects also require to start abstinence or take effective non drug contraceptive measures two weeks before entering the study);
- •7\. Subjects who can communicate well with researchers, understand and comply with the requirements of this study, and understand and sign the informed consent.
Exclusion Criteria
- •1\. Patients with allergic constitution or known allergy to study drug / similar drug;
- •2\. Patients who often use sedatives, sleeping pills or other addictive drugs; patients who have a history of drug abuse or positive drug abuse screening within 12 months before the first administration;
- •3\. Alcoholics or patients who drink more than 14 units of alcohol per week (1 unit \= 360ml of beer or 45ml of spirits or 150ml of wine with 40% of alcohol), patients who are addicted to smoking or quit smoking for less than 3 months, patients who are positive in alcohol breath test and nicotine test, and can not be banned from smoking or alcohol during the test period;
- •4\. Patients who used any prescription medicine or Chinese herbal medicine supplement within one month before the first administration; patients who used any over\-the\-counter medicine (OTC), food supplement (including vitamins, calcium tablets, etc.) within two weeks before the first administration; patients who used contraceptive within two weeks before the first administration;
- •5\. Patients who participated in other clinical trials and took the study drug within 3 months before the first administration;
- •6\. The patients who participated in blood donation (including component blood donation) or lost 400ml blood within 3 months before the first administration, and the patients who participated in blood donation (including component blood donation) or lost 200ml blood within 1 month before screening, or received blood transfusion;
- •7\. There was a history of autonomic nervous dysfunction and / or current history (such as recurrent syncope, palpitation, etc.) within 3 years before the first administration;
- •8\. Patients with previous history of cardiovascular, liver, kidney, lung, digestive tract, nervous system diseases, and any history or condition that may significantly affect drug absorption, distribution, metabolism and excretion. Any medical history or condition that may be hazardous to the subjects participating in the trial. Researchers should consider the following medical history or conditions: inflammatory gastroenteritis, gastroesophageal reflux, gastrointestinal or rectal bleeding; history of pancreatic injury or pancreatitis; major surgical history such as gastrectomy, gastroenterostomy, or enterotomy; history of acute and chronic renal insufficiency, history of kidney transplantation;
- •9\. Screening the patients with severe vomiting and diarrhea in the previous week;
- •10\. Pregnant and lactating female subjects and those of childbearing age who could not use contraception as required;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Study to evaluate the safety of human immune globulin in patients withprimary immunodeficiency diseases.EUCTR2011-005015-82-Outside-EU/EEAOctapharma AG20
Not yet recruiting
Phase 1
Clinical study to assess the safety and tolerability of administration, directly into a vein, of human umbilical cord and placental blood plasma (Plasmacord®) in patients with Severe acute respiratory syndrome resulting from Sars-Cov-2 infection (fever, cough headache, muscle aches and difficulty breathing)RBR-4pfygrCRYOPRAXIS - CRIOBIOLOGIA LTDA
Completed
Phase 3
Clinical study to evaluate the safety and tolerability of immunoglobulin intravenous (human) 10% (NewGam) administered at high infusion rates to patients with primary immunodeficiency diseasesISRCTN11002924Octapharma AG (Switzerland)35
Recruiting
Not Applicable
safety and effectiveness of Soreze gel in pressure ulcerHealth Condition 1: L899- Pressure ulcer of unspecified siteCTRI/2021/06/034297Amaterasu Lifesciences
Unknown
Phase 2
A study to evaluate ABT-450 with Ritonavir (ABT-450/r) and ABT-267 in Japanese adults with chronic Hepatitis C Virus infectioJPRN-jRCT2080221883AbbVie GK96